Bayesian integration of longitudinal and survival outcomes in Alzheimer's disease prediction
Open Access
- 2 September 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70094
Abstract
INTRODUCTION: Accurate prediction of Alzheimer's disease (AD) dementia onset and progression to mild cognitive impairment (MCI) is crucial for early intervention and clinical trial design. This study presents a predictive framework leveraging Bayesian model averaging (BMA) with a multivariate functional mixed model (MFMM) to integrate multivariate longitudinal outcomes and survival data. METHODS: The training cohort included 1012 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The validation cohort comprised 2087 participants from the National Alzheimer's Coordinating Center (NACC). BMA methods, including stacking and pseudo‐BMA+, aggregated predictions across candidate models to enhance accuracy and robustness. Predictive performance was evaluated using the C‐index, a measure of discrimination. RESULTS: Compared to the composite model, BMA improved prediction accuracy. The C‐index was 0.777 (stacking) and 0.771 (pseudo‐BMA+) in ADNI and 0.743 and 0.738 in NACC. DISCUSSION: This framework offers a robust tool for personalized medicine, enabling accurate predictions and enhanced generalizability across diverse populations. Highlights: We introduced a novel joint modeling framework integrating multivariate longitudinal outcomes (Mini‐Mental State Examination and Clinical Dementia Rating Sum of Boxes) with survival data to predict Alzheimer's disease dementia onset and progression. We validated the framework across complementary datasets: Alzheimer's Disease Neuroimaging Initiative (training) and National Alzheimer's Coordinating Center (NACC; validation), with NACC providing a demographically diverse population to assess generalizability. The model enhanced predictive accuracy using Bayesian model averaging, which synthesizes insights across multiple models to reduce uncertainty and improve robustness. The model demonstrated consistent and clinically relevant performance, supporting its applicability for early intervention, precision medicine, and clinical trial design.Keywords
Funding Information
- National Institute on Aging (R01AG064803)
- National Institute on Aging (P30AG072958)
This publication has 21 references indexed in Scilit:
- Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performanceNeurobiology of Aging, 2012
- Longitudinal Change of Biomarkers in Cognitive DeclineArchives of Neurology, 2011
- survcomp: an R/Bioconductor package for performance assessment and comparison of survival modelsBioinformatics, 2011
- Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging InitiativeArchives of General Psychiatry, 2011
- Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate PredictorsPLOS ONE, 2011
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's DiseaseBiological Psychiatry, 2008
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982
- Evaluating the yield of medical testsJAMA, 1982
- “Mini-mental state”Journal of Psychiatric Research, 1975